Overview

• The court’s July 3 interim order prohibits Patanjali Ayurved from publishing or broadcasting any disparaging or misleading advertisements targeting Dabur Chyawanprash.
• Justice Mini Pushkarna led the bench that allowed Dabur’s petition after finding Patanjali’s claims of exclusive Ayurvedic conformity potentially deceptive.
• Dabur’s counsel argued that Patanjali’s ads falsely presented its Chyawanprash as the sole authentic formula, labeled a 40-herb variant “ordinary,” and questioned competitor safety with unverified mercury allegations.
• Patanjali’s legal team countered that its formulation adhered to classical Ayurvedic texts, employed over 51 herbs, and met all safety standards for human consumption.
• The dispute remains active with the next Delhi High Court hearing scheduled for July 14, highlighting ongoing judicial oversight of health-related marketing claims.